IGM Biosciences has signed a clinical trial partnership and supply agreement with ADC Therapeutics to analyse the combination of imvotamab and Zynlonta (loncastuximab tesirine-lpyl) to treat relapsed/refractory (R/R) B cell non-Hodgkin’s lymphoma (NHL).
Imvotamab is an IGM -based CD20 x CD3 T cell engaging bispecific antibody of IGM while Zynlonta is a CD19-directed antibody-drug conjugate (ADC) of ADC Therapeutics.
As per the deal, IGM will carry out clinical testing to assess the safety and efficacy of imvotamab plus Zynlonta to treat R/R NHL patients.
ADC Therapeutics will offer the clinical capabilities of Zynlonta and will deliver the drug to back the trial.
IGM plans to commence the trial in the first quarter of next year.
Favourable mechanistic rationale and preclinical findings indicating robust activity of the combination therapy are the basis for this clinical partnership.
IGM Biosciences chief medical officer Chris Takimoto said: “Patients with B cell non-Hodgkin’s lymphoma are in need of efficacious and well-tolerated treatments.
“We are excited to enter this collaboration with ADC Therapeutics that aims to provide a novel combination regimen targeting both CD19- and CD20-expressing cells for patients with relapsed/refractory B cell non-Hodgkin’s lymphoma.
“We look forward to working with the team at ADC Therapeutics and initiating clinical testing in the first quarter of 2023.”
Zynlonta received US Food and Drug Administration (FDA) approval for treating adults with R/R large B-cell lymphoma following two or more lines of systemic therapy.
An Imvotamab 100mg dose had demonstrated a 50% complete response rate.
Cytokine release syndrome was observed in under 20% of the 28 subjects who received the treatment in the titration dosing cohorts as per data that was reported last year.
In March this year, IGM and Sanofi signed an exclusive worldwide collaboration agreement to create, develop, produce, and commercialise IgM antibody agonists for oncology, immunology, and inflammation targets.